Everest Medicines' Zetomipzomib IND Accepted in China

-- Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis –  -...

December 04, 2023 | Monday | News
Pfizer Reveals Positive Phase 2b Results for Obesity Drug Danuglipron

Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9.5% at 26 weeks While most common adv...

December 04, 2023 | Monday | News
Junshi Biosciences' Toripalimab Application Accepted by Australia’s TGA

For the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC), and for toripalimab, as a single agent...

December 04, 2023 | Monday | News
FDA Approves Agilent's PD-L1 IHC 22C3 pharmDx for Gastric Adenocarcinoma

Agilent  announced that it has received FDA approval for the use of PD-L1 IHC 22C3 pharmDx as a diagnostic tool to aid in identifying patients with Ga...

November 29, 2023 | Wednesday | News
Mesoblast Seeks Orphan Drug Status for Rexlemestrocel-L in Treating Severe Congenital Heart Disease

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that it has filed for orphan ...

November 27, 2023 | Monday | News
Junshi Biosciences' VV116 COVID-19 Treatment Hits Lancet Infectious Diseases in Phase 3 Study Results

The paper presents final analysis results from a multicenter, double-blind, phase 3, randomized controlled study (NCT05582629) evaluating the efficacy and ...

November 24, 2023 | Friday | News
Genentech, NVIDIA Partner for Strategic AI Collaboration in Drug Discovery

- Collaboration leverages expertise in artificial intelligence from Genentech and NVIDIA to unlock scientific innovation and empower R&D at a sca...

November 22, 2023 | Wednesday | News
Certara Launches Simcyp™ Software to Enhance Drug Formulation Efficiency

Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,  announced the introduction of Simcyp™ Biopharmaceutics software. It is designed...

November 22, 2023 | Wednesday | News
Hovione Acquires ExtremoChem for Enhanced Biopharmaceutical Stabilization and Delivery

Hovione has acquired ExtremoChem Lda, a start-up company with a portfolio of rare sugars, synthetic analogues of the natural molecules found in extremoph...

November 21, 2023 | Tuesday | News
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

"The NMPA approval of vebreltinib is an important milestone toward providing a new treatment option for patients with MET exon 14 skipping NSCLC in China. ...

November 17, 2023 | Friday | News
Vertex and CRISPR Therapeutics Granted Historic Approval for CASGEVY™, the World's First CRISPR/Cas9 Gene-Edited Therapy, by UK MHRA to Combat Sickle Cell Disease and Beta Thalassemia

 - First regulatory authorization of a CRISPR-based gene-editing therapy in the world – - CASGEVY is indicated for the treatment of sickle cell...

November 17, 2023 | Friday | News
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneou...

November 14, 2023 | Tuesday | News
Charles River and Aitia Partner to Advance Logica in Neurodegenerative and Oncology Discoveries

Strategic partnership includes co-development of patient-derived xenograft (PDX) Digital Twins for in vivo oncology research Charles River to make an eq...

November 14, 2023 | Tuesday | News
STADA, Alvotech Get Positive CHMP Nod for Europe's First Ustekinumab Biosimilar to Stelara

Positive CHMP opinion for Uzpruvo biosimilar is based on comprehensive package comprising analytical, non-clinical and clinical similarity data, includin...

November 13, 2023 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2023 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in